Back to Cell Types

NCI-H508Homo sapiens (Human)Cancer cell line

Also known as: H-508, H508, NCIH508, NCI H508

🤖 AI SummaryBased on 14 publications

Quick Overview

Human colorectal cancer cell line with KRAS and BRAF mutations.

Detailed Summary

The NCI-H508 cell line is a human colorectal cancer cell line derived from a colon tumor. It is characterized by specific genetic mutations in KRAS and BRAF, which are commonly associated with resistance to EGFR-targeted therapies. These mutations play a critical role in the development and progression of colorectal cancer, making NCI-H508 a valuable model for studying molecular mechanisms of drug resistance and for developing targeted therapeutic strategies. The cell line is also used in research to understand the genetic and epigenetic alterations that contribute to cancer heterogeneity and treatment outcomes.

Research Applications

Study of KRAS and BRAF mutations in colorectal cancerInvestigation of EGFR-targeted therapy resistanceMolecular mechanisms of cancer progressionDevelopment of targeted therapeutic strategies

Key Characteristics

KRAS mutationsBRAF mutationsResistance to EGFR inhibitorsModel for colorectal cancer research

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1564
Species	Homo sapiens (Human)
Tissue Source	Abdominal wall[UBERON:UBERON_0003697]

Donor Information

Age	55
Age Category	Adult
Sex	Male
Race	caucasian

Disease Information

Disease	Cecum adenocarcinoma
Lineage	Bowel
Subtype	Colon Adenocarcinoma
OncoTree Code	COAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000360_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg273His (c.818G>A)	Homozygous	-	Unknown, PubMed=16264262
MutationSimple	PIK3CA	p.Glu545Lys (c.1633G>A)	Heterozygous	-	from parent cell line MCF-7
MutationSimple	BRAF	p.Gly596Arg (c.1786G>C)	Heterozygous	-	from parent cell line NCI-H508

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

11,12

D13S317

8,12

D16S539

12

D18S51

18

D19S433

14

D21S11

29,32.2

D2S1338

18,19,27

D3S1358

14,17

D5S818

12

D7S820

8,12

D8S1179

12

FGA

24,25

Penta D

12

Penta E

10,12

TH01

9,9.3

TPOX

8,11

vWA

15,16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Genomic determinants of protein abundance variation in colorectal cancer cells.

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Cell Rep. 20:2201-2214(2017).

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Mol. Cancer 16:116.1-116.16(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

Nat. Commun. 6:7002.1-7002.10(2015).

Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer.

Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.

Clin. Cancer Res. 21:2157-2166(2015).

Epigenetic and genetic features of 24 colon cancer cell lines.";

Hektoen M., Lind G.E., Lothe R.A.

Oncogenesis 2:e71.1-e71.8(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

Br. J. Cancer 103:340-346(2010).

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Cancer Res. 70:5901-5911(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.

Camps J., McNeil N.E., Difilippantonio M.J., Ried T.

Genes Chromosomes Cancer 49:204-223(2010).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

Biology of colorectal and gastric cancer cell lines.";

Park J.-G., Gazdar A.F.

J. Cell. Biochem. Suppl. 24:131-141(1996).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Characteristics of cell lines established from human colorectal carcinoma.

Johnson B.E., Gazdar A.F.

Cancer Res. 47:6710-6718(1987).